| Invested through |
|
|---|---|
| Asset Classes | Listed equity |
| Impact strategy | Impact Equities and Bonds |
| ISIN code | NL0015002CX3 |
| Industry group | Healthcare |
| Aligned with SDGs |
Qiagen is a Netherlands-based provider of biological sample technologies. The company produces consumables and instruments for human disease diagnostics, pharmaceutical research, and academic research and diagnostics beyond human diseases. Its product portfolio encompasses consumable kits of sample and assay technologies, automation systems, and bioinformatics.
Qiagen operates and reports as one operating segment serving over 500,000 customers in more than 130 countries around the globe, with around half of revenues coming from products for customers in molecular diagnostics and the other half from customers in life sciences.
Investment rationale
Qiagen's products support physicians in the diagnosis of illnesses and selection of treatment and also scientists and clinicians to advance scientific discovery and ultimately improve patient outcomes.
Apart from the positive impact of its products, Qiagen promotes access to healthcare in underserved regions by offering product alternatives for resource-poor settings, by making product donations to support underserved populations, and by sponsoring measures to improve the local healthcare infrastructure in underserved regions.
Alignment with Triodos Transitions: In total, 70% of the revenues of the company is aligned with the Wellbeing transition. The contribution to the Wellbeing transition comes from 70% of revenues related to the impact objective Health Care.